Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Thomas Bieber et al.|New England Journal of Medicine|2016Cited by 2k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al.|British Journal of Dermatology|2020Cited by 590
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S. Paller, Adelaide A. Hebert, Wynnis L. Tom et al.|Journal of the American Academy of Dermatology|2016Cited by 564
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman‐Yassky, Alan D. Irvine, Henrique D. Teixeira et al.|The Lancet|2021Cited by 538
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisEric L. Simpson, Ashish Bansal, Amy S. Paller et al.|JAMA Dermatology|2019Cited by 505